Aug. 14, 2002 -- Risperidone was effective for the control of disruptive behavior in children with subaverage intelligence, according to results of a double-blind, parallel group study reported in the ...

TITUSVILLE, N.J., Aug. 22 -- The U.S. Food and Drug Administration (FDA) today approved RISPERDAL(R) (risperidone) for the treatment of schizophrenia in adolescents ages 13-17 and for the short-term ...

Aug. 1, 2002 -- Risperidone was well tolerated and effective in treating behavioral problems in autistic children, according to the results of a multisite, double-blind, randomized trial reported in ...

Johnson & Johnson, still reeling from settling two Ohio opioid-related lawsuits for more than $20 million, was slapped with an $8 billion judgment on Tuesday over its antipsychotic drug Risperdal. A ...

A Philadelphia judge has reduced the amount of punitive damages Johnson & Johnson JNJ0.04%increase; green up pointing triangle must pay in a lawsuit over its antipsychotic Risperdal to $6.8 million ...

Risperidone is an antipsychotic with known side effects that clinicians must balance against its benefits for a subset of autistic people. Although it can, for some autistic people, help reduce ...

NEW YORK, June 21 (Reuters) - Johnson & Johnson on Thursday said U.S. regulators have given conditional approval for use of its drug Risperdal as a treatment for adolescents with schizophrenia and ...

It might sound like a candidate for the So What? award, but the FDA's approval of the "atypical" antipsychotic Risperdal for use in children and adolescents is a landmark decision. The drug is already ...

Johnson & Johnson (NYSE:JNJ) says it has settled most of the lawsuits in the anti-psychotic drug Risperdal cases and has recorded $800 million in expenses in connection with the agreement. The medical ...